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Background: Early drug intervention in childhood disorders aims to maximize individual
potential in the short- and long-term. Consistently, juvenile exposure to psychostimulants,
such as methylphenidate (MPH), reduces risk for substance use in animals and
sub-populations of individuals with attention deficit hyperactivity disorder (ADHD). We
investigated the effects of MPH on brain plasticity via dopamine receptor D3 (D3R) and
brain-derived neurotrophic factor (BDNF) expression in developing rats.
Methods: Between postnatal days 20–35, rat pups were administered saline vehicle (Veh)
or MPH (2mg/kg), the D3R-preferring agonist ±7-OHDPAT, or the antagonist nafadotride
(0.05mg/kg) alone, or in combination with MPH twice a day. In adulthood, subjects were
challenged to Veh or cocaine (10mg/kg for two days). The prefrontal cortex was analyzed
for protein and mRNA levels of total BDNF, its splice variants I, IIc, III/IV, and IV/VI, and D3
receptors. A separate group of subjects was assessed for splice variants at 20, 35, 40,
and 60 days of age.
Results: Across age strong correlations were evident between Drd3 and Bdnf mRNA
levels (r = 0.65) and a negative relationship between Drd3 and exon IIc after MPH
treatment (r = −0.73). BDNF protein levels did not differ between Veh- and MPH subjects
at baseline, but were significantly lower in MPH-treated and cocaine challenged subjects
(30.3 ± 9.7%). Bdnf mRNAwas significantly higher in MPH-treated subjects, and reversed
upon exposure to cocaine. This effect was blocked by nafadotride. Furthermore, Bdnf total
and Bdnf splice variants I, IIc, III/IV, and IV/VI changed across the transitions between
juvenility and late adolescence.
Conclusions: These data suggest a sensitive window of vulnerability to modulation of
BDNF expression around adolescence, and that compared to normal animals, juvenile
exposure to MPH permanently reduces prefrontal BDNF transcription and translation upon
cocaine exposure in adulthood by a D3R-mediated mechanism.
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INTRODUCTION
Children with Attention Deficit Hyperactivity Disorder (ADHD)
often respond favorably to psychostimulant therapy, contribut-
ing to its use by 61% of children with ADHD between the
ages of 6–13 years (Dalsgaard et al., 2013). The most commonly
prescribed stimulant is methylphenidate (MPH). MPH predom-
inantly affects the dopamine and noradrenergic systems, with
recent evidence showing a role of the dopamine D3 receptor
(D3R) in ADHD-associated behaviors in animals (Andersen et al.,
2008; Barth et al., 2013). For example, D3R antagonists reduce
hyperactivity and facilitate object recognition in DAT knockout
mice, which have been used to model an ADHD phenotype.
Other studies further localize D3R actions in object recognition
to the prefrontal cortex (Watson et al., 2012).
Childhood/juvenile exposure to psychostimulants during this
time of elevated plasticity produces effects that are opposite of
those observed in drug-exposed adult animals (Brandon et al.,
2001; Dow-Edwards and Busidan, 2001; Andersen et al., 2002;
Bolanos et al., 2003; Andersen, 2005). For example, juvenile,
but not adult, exposure to cocaine reduces drug seeking later in
life (Dow-Edwards and Busidan, 2001; Andersen et al., 2002).
Similarly, juvenile MPH decreases Drd3 mRNA in the prefrontal
cortex (PFC) (Andersen et al., 2008), in contrast to an increase
in the same region in adult, stimulant-exposed animals (Le Foll
et al., 2005). While most adult studies have focused on D3R
changes in the nucleus accumbens (Everitt and Robbins, 2000; Le
Foll et al., 2005), the reduction in D3R following juvenile MPH
exposure is not evident in that region (Andersen et al., 2008).
Rather, the juvenile MPH effect on D3R and an MPH-induced
place aversion was recapitulated by juvenile treatment with
the D3R agonist ±7-OHDPAT (Andersen et al., 2008). Finally,
microinjections of ±7-OHDPAT into the PFC reversed aversion,
resulting in a preference for cocaine-associated environments.
Cue responsiveness to drug-associated contexts depends on
neuroplasticity associated with brain-derived neurotrophic fac-
tor (BDNF) levels in adult animals within the prelimbic (pl) PFC
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(Berglind et al., 2007). Adult BDNF levels are transiently ele-
vated following an acute injection of cocaine in both the PFC
and the nucleus accumbens (NAc), with sustained elevations of
Bdnf and Drd3 mRNA found 60 days later in the NAc (Le Foll
et al., 2005). Juvenile exposure to MPH reduces Bdnf mRNA in
the striatum and the hypothalamus with no change in the cingu-
late cortex during peri-adolescence (Chase et al., 2007). Similar
findings of no change in Bdnf mRNA were evident in the ventral
tegmental area both immediately after treatment and long-term
(Warren et al., 2011). However, the enduring effects of MPH
exposure interact with development to manifest fully later in life
(Andersen, 2005; Brenhouse and Andersen, 2011). Therefore, the
lack of changes in BDNF expression as observed by Chase et al.
(2007) in the PFC andWarren et al. (2011) in the ventral tegmen-
tal area could have been undetectable, because the window of
observation was too early. In order to investigate the time course
of D3 receptors and BDNF expression in the developing PFC,
we examined the postnatal expression of these two indices and
their inter-relationship (Experiment 1). We also examined how
previous exposure to MPH may or may not modify BDNF lev-
els to cocaine later in life (Experiment 2). As we suspect that
D3 receptors modify BDNF expression in the medial PFC, we
manipulated D3 activity in vivo using juvenile exposure to MPH,
±7-OHDPAT, and the D3R antagonist nafadotride (Experiment
3). Ultimately, we were interested in how juvenile exposure to
MPH or a D3R-preferring agonist modulates BDNF expression
later in life at baseline and following a 2-day unbiased place
conditioning paradigm to 10mg/kg cocaine.
Environmental influences, such as drug exposure during sen-
sitive periods, can further modulate synaptic structure by altering
the expression of Bdnf splice variants (Boulle et al., 2012). Such
specific modulation of splice variants permits both spatial and
temporal regulation of BDNF expression that in turn, can lead
to the precise building of synaptic structure and respond to
environmental demands. Understanding how specific splice vari-
ants of the Bdnf gene change across age may provide insight
into the nature of maturation of different parts of the neu-
ron. Exon I and II are specific to neurons, whereas exons
III and IV are found in non-neural tissue as well (Nakayama
et al., 1994). The exon I splice variant is expressed primar-
ily in the soma and dendrites, whereas exon II is predomi-
nantly in the dendrites, and exon IV is restricted to the soma
(Boulle et al., 2012).
Empirical data suggest that different exons are altered fol-
lowing experiences in a semi-unique manner. For example,
exon II seems to be preferentially regulated in reward circuits
(McCarthy et al., 2012). Sadri-Vakili et al. (2010) demonstrated
that chronic cocaine increased Bdnf exon IV in the PFC of
adult rats. Exon IV contains the binding sites for CREB and
MeCP2 and plays a role in cognitive processes and learning and
memory—such as those required for encoding drug-associated
cues (Boulle et al., 2012; McCarthy et al., 2012). While BDNF
changes have already been associated with addiction-related alter-
ations in structure and function, themajority of these studies have
been performed following adult drug exposure paradigms. We
are particularly interested in whether exon IV changes following
juvenile exposure to MPH, which we have shown increases CREB
expression (Andersen et al., 2002). To investigate whether stimu-
lants have unique effects on Bdnf splice variants, we determined
how Bdnf total, and different 5′ exons splice variants (exons I, IIc,
III/IV, and IV/VI), change across age within the late maturing
PFC (Experiment 4). Here, we used quantitative Real-Time PCR
(qRT-PCR) to examine changes in Bdnf exons, as protein-labeling
antibodies for the specific exons are not yet available.
MATERIALS AND METHODS
SUBJECTS
Lactating female Sprague-Dawley rats obtained from Charles
River were housed with their litters on a 12 h/12 h light/dark cycle
with lights on at 07:00 h with food and water provided ad libidum.
Litters were culled to 8 pups of equal numbers of males and
females on postnatal day 1 (P1), and were weaned at P21. Care
was taken to distribute each condition to one male from each lit-
ter. Only males were used for these studies, with the remaining
littermates used in other studies. The overall experimental design
is found in Figure 1.
DRUGS
MPH HCl (d,l-MPH), ±7-OHDPAT, nafadotride, and cocaine
HCl were obtained from Sigma (St. Louis, MO). Drugs were dis-
solved in 0.9% saline (vehicle) and administered in a volume of
1ml/kg. Our earlier study demonstrated no behavioral difference
with i.p. vs. oral administration in place conditioning (Brenhouse
et al., 2009).
qRT-PCR
qRT-PCR was performed as described (Andersen et al., 2008).
Briefly, brains were rapidly dissected into the mPFC. Sections
were snap-frozen in TriReagent solution (Sigma) and stored
at −80◦C until further analysis. Samples were homogenized,
total RNA extracted, DNAse digested (Ambion, Austin, TX),
and reverse transcribed into cDNA using the SuperScript II
FIGURE 1 | A schematic showing the overall experimental design that
includes the timing of drug treatments. Vehicle (Veh), methylphenidate
(MPH), conditioned place preferences (CPP). Ages of rats are in days. (A–D)
presents a schematic of the paradigms used for Experiments 1–4.
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First-Strand Synthesis System (Life Technologies, Foster City,
CA). cDNA samples were analyzed by qPCR using the iQ SYBR
Green Supermix (BioRad). Amplifications were performed in a
total volume of 20µl with 40 nMol primers for each reaction on
an Opticon MJ Thermocycler; MJ Research (Watertown, MA).
The following published primer sequences were used: Bdnf exons
I, II, II, and (Tsankova et al., 2006) Bdnf total (Asai et al., 2007),
and Drd3 and Gapdh (Andersen et al., 2008).
Bdnf total: F: 5′-ACTCTGGAGAGCGTGAATGG-3′ R: 5′-TAC
TGTCACACACGCTCAGC-3′
Exon I: F: 5′-CCTGCATCTGTTGGGGAGAC-3′ R: 5′-GCC
TTGTCCGTGGACGTTTA-3′
Exon II: F: 5′-CTAGCCACCGGGGTGGTGTAA-3′ R: 5′-AGGA
TGGTCATCACTCTTCTC-3′
Exon III F: 5′-CTTCCTTGAGCCCAGTTCC-3′ R: 5′-CCGTGG
ACGTTTACTTCTTTC-3′
Exon IV F: 5′-CAGAGCAGCTGCCTTGATGTT-3′ R: 5′-GCC
TTGTCCGTGGACGTTTA-3′
Drd3: F: 5′-AAGCGCTACTACAGCATCTGC-3′ R: 5′-GGATAA
CCTGCCGTTGCTGAG-3′
Gapdh: F: 5′-AACTCCCATTCTTCCACCTTTG-3′ R: 5′-CCC
TGTTGCTGTAGCCATATTC-3′
The Bdnf exon primers were verified by sequence alignment
using deposited sequences in GenBank: Exon I, transcript variant
I (Accession EF125675); Exon II: transcript variant IIc (Accession
EF125678); Exon III: transcript variant III (Accession EF125686);
Exon IV: transcript variant IV (Accession EF125679). A new
nomenclature for Bdnf transcript variants has recently been sug-
gested by Aid et al. (2007). Accordingly, our primer sequences for
exon II, III, and IV amplify new exons IIc, IV, and VI, respectively.
Thus, for each exon both the old and the new nomenclature are
indicated.
DESIGN
Experiment 1: The relationship between Drd3 and Bdnf mRNA
IN VIVO
Subjects and Design.mRNA from the PFC was assessed to deter-
mine the nature of the relationship between Bdnf total and Drd3
across age. Rats were sacrificed at 4 ages: P25, 35, 40, and 60
representing juvenile, early adolescent, mid adolescent and late
adolescent stages respectively (Figure 1A). The PFC was rapidly
(<1min) dissected out onto chilled glass plates. The sample was
then processed for qRT-PCR as described in detail above (3.3). An
n = 6 for P25 and n = 5 for P35, 40, and 60 were used.
Experiment 2: Measurement of Bdnftotal mRNA and BDNF protein
levels following MPH treatment with and without cocaine
conditioning
Drug treatment paradigm. Subjects were weighed daily at 09:00 h
and injected with either MPH (2mg/kg) or saline vehicle (Veh)
between P20-35 (see Figure 1B; Andersen et al., 2002, 2008.
The second injection was administered 4 h later at 13:00 h. The
dose of MPH was selected on the basis of previous studies
(Andersen et al., 2002), and approximates a clinically relevant
dose in humans based on plasma levels (Wargin et al., 1983;
Kuczenski and Segal, 2002). After P35, the rats received no fur-
ther drug treatment until behavioral testing or sacrifice for the
pharmacological studies 25 days later at P60.
Design. To determine whether PFC BDNF levels and MPH expo-
sure interacted with place conditioning to cocaine, we examined
mRNA and protein levels. Drug-exposed subjects were housed
with littermates and grown to P60, when they either (1) remained
naïve to cocaine exposure (cocaine-naïve) or 2 underwent place
conditioning to cocaine (10mg/kg, i.p.). The 10mg/kg dose of
cocaine was chosen based on prior studies (Andersen et al., 2002;
Carlezon et al., 2003) that demonstrated a clear differentiation
of place conditioning effects between Veh animals. Our earlier
study with these animals showed that the Veh subjects demon-
strated a minimal preference for cocaine-associated environment,
whereas the MPH animals demonstrated a significant place aver-
sion (Andersen et al., 2008). Two sets of subjects were run: one
set for Bdnf mRNA (n = 6) and the second set for BDNF protein
(n = 5).
Cocaine place conditionin.Unbiased place conditioning, accord-
ing to standard laboratory methods (Andersen et al., 2002;
Carlezon et al., 2003), occurred in a 3-chamber apparatus. This
chamber consisted of two large (24 × 18 × 33) side compart-
ments separated by a small (12 × 18 × 33 cm) middle compart-
ment. Screening was conducted for 30min on day 1. Rats were
placed in the middle compartment and allowed to freely explore
the apparatus. Rats that demonstrated a clear preference for either
side (>18 of 30min) were eliminated from further testing. Two
days of conditioning (with 2 sessions per day) occurred on day
2 and 3 for 60min, and robust conditioning under these condi-
tions was observed (Andersen et al., 2002; Carlezon et al., 2003).
During the conditioning sessions, rats received a 1ml/kg, i.p.
injection of Veh in the morning (09:00 h) and confined to one
side. The animals were then returned to the home cage. Four
hours later, rats received 10mg/kg cocaine and confined to the
other side. The dose of cocaine for the place conditioning experi-
ments was based on previous results that demonstrated consistent
place aversion in MPH-exposed male rats at P60 (Andersen et al.,
2002; Carlezon et al., 2003). Sides differed in floor texture, wall
colors, and lighting, and assignments were counterbalanced. On
day 4, rats were permitted to freely explore the entire apparatus
for 30min in a drug-free state.
BDNF protein immunoassays. BDNF protein was extracted
from the PFC. Dissected tissue was weighed and homogenized
in 10 vol/wt of cold extraction buffer consisting of: 100mM
Tris/HCl, ph = 7.0, 2% bovine serum albumin, 4mM EDTA,
2% Triton-X, and the protease inhibitors aprotinin (5µg/ml),
benzamidine HCl (157µg/ml), pepstatin A (0.1µg/ml), and
phenylmethylsulfonyl fluoride (PMSF; 17µg/ml). Homogenates
were centrifuged at 14,000 rpm for 30min at 4◦C and
the supernatant was used in the assay. BDNF protein was
quantified using the ChemiKine BDNF Sandwich ELISA kit
(Chemicon, Temecula, CA) according to the manufacturer’s
directions. Samples were run in duplicate and quantified
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using standards run simultaneously with the experimental
samples.
Experiment 3: Relationship between Bdnftotal mRNA and D3R drug
treatment
Subjects. Subjects were exposed to ±7-OHDPAT (0.3mg/kg; n =
6) between P20-35 or Veh (n = 6; Figure 1). To further confirm
that the effects of MPH were mediated by the D3 receptor, a
separate group of subjects was treated with MPH (2mg/kg, i.p.;
n = 6), nafadotride (0.05mg/kg; n = 6), a combination of MPH
and nafadotride (MPH/Nafad; n = 6) twice daily between the
ages of P20-35 (Andersen et al., 2002).
Design. Subjects were tested with place conditioning to environ-
ments associated with 10mg/kg cocaine at P60 (Andersen et al.,
2008) and sacrificed 24 h after the last cocaine injection, the PFC
rapidly dissected out, and Bdnf mRNA changes determined by
qRT-PCR (Figure 1C).
Experiment 4: Age and drug effects on the Bdnf splice variants
exons I, IIc, III/IV, IV/VI and Drd3
Subjects. Rats the ages of 20, 35, 40, and 60 days were used in
these studies (n = 6/age). The 20 and 35 days ages were selected
to characterize the expression of exons during the drug exposure
period, 40 and 60 days represent short- and long-term ages for the
paradigm.
Design. The PFC was dissected and processed for mRNA for
exons I, IIc, III/IV, IV/VI, and Drd3 across age. Bdnf exons
were assessed from subjects exposed to MPH or Veh as juveniles
(Figure 1D).
DATA ANALYSIS
The expression of the Bdnf exons was normalized to the house-
keeping gene product Gapdh. Linearity (r = 0.9 or better) and
detection limit of the assay were determined in successive 10-
fold serial dilutions, performed in triplicate, and an optimal
amount of template was chosen for the quantitative analy-
sis. Quantification was performed at a threshold detection line
(“threshold cycles,” Ct value). The Ct of each gene was nor-
malized against Gapdh, which was run simultaneously for each
marker. Expression levels and differences between treatment and
Veh groups were determined according to the 2−Ct or 2−Ct
method, respectively (Livak and Schmittgen, 2001). Comparisons
were made between drug groups with a two-tailed Student’s t-test
or an ANOVA (SPSS); statistical significance was set at p < 0.05.
Data were expressed as mean ± s.e.m.
RESULTS
EXPERIMENT 1: THE RELATIONSHIP BETWEEN Drd3 AND Bdnf mRNA
IN VIVO
mRNA from the PFC across age of animals wasmeasured to deter-
mine a relationship between Bdnf total and Drd3. Age itself had a
significant effect onDrd3 [F(3,17) = 7.87, P < 0.001], but did not
significantly influence Bdnf mRNA (p = 0.1). Regression analysis
with ANCOVA showed that Drd3, when co-varied for age, signif-
icantly predicted Bdnf mRNA [F(1,19) = 18.20, P < 0.001] and
accounts for 49% of Bdnf changes (Figure 2).
FIGURE 2 | Correlation between Drd3 and Bdnf mRNA from the PFC of
developing rats at the ages of 20, 35, 40, and 60 days.
FIGURE 3 | Bdnf mRNA changes following juvenile MPH treatment
between 20 and 35 days of age relative to controls. (left) Veh or MPH
rats were assessed at P60 without prior cocaine place conditioning (naïve)
or after place conditioning to 10mg/kg cocaine for 2 days (tested).
∗p < 0.05. (right) A separate group of subjects was exposed to the
D3R-preferring agonist ±7-OHDPAT between P20-35 and assessed for
Bdnf at P60. #p < 0.06 Mean ± SE for n = 6 subjects shown.
EXPERIMENT 2: Bdnf total mRNA AND PROTEIN LEVELS FOLLOWING
MPH TREATMENT
The relationship between PFC Bdnf mRNA levels and MPH
exposure interacted significantly with whether or not the ani-
mals were behaviorally tested with cocaine [Exposure × Testing
interaction: F(1,12) = 6.01, P < 0.05]. Bdnf mRNA levels were
elevated in MPH subjects relative to Veh controls, and this rela-
tionship reversed following behavioral testing to cocaine at P60
[Figure 3 (left)]. Similar to the effects of MPH exposure, juve-
nile treatment with the D3R-preferring agonist±7-OHDPAT also
increased Bdnf mRNA [Figure 3 (right)] in behaviorally-naïve
subjects.
As observed in the mRNA levels, a significant interaction was
observed in BDNF protein levels as a result of cocaine test-
ing [Exposure × Testing interaction: F(1,29) = 5.35, p < 0.05].
Baseline levels of BDNF protein (pg/ml) did not significantly
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differ between MPH and Veh subjects [t(8) = 0.83, p = 0.4; see
Figure 3). After cocaine administration at P60, however, BDNF
protein levels in Veh subjects increased 253.1 ± 28.9% relative to
cocaine naïve controls. In contrast, MPH-exposed subjects had
a slightly smaller percent increase (222.2 ± 24.4%) relative to
cocaine naïve levels, consistent with lower Bdnf mRNA levels in
this group.
EXPERIMENT 3: RELATIONSHIP BETWEEN Bdnf total mRNA, D3R, AND
MPH TREATMENT
Consistent with the data in Experiment 2, following juvenile
MPH exposure and place conditioning to cocaine, Bdnf mRNA
levels were significantly reduced 30.3 ± 9.7% when compared
to the Veh exposed subjects [t(11) = 2.69, p < 0.03; Figure 4]. In
contrast, Bdnf mRNA significantly increased 35% following juve-
nile exposure to the D3R antagonist, nafadotride, when compared
with Veh controls [t(12) = 2.65, p < 0.03]. No significant differ-
ence was observed between the Veh and the MPH/Nafad subjects
[t(13) = 0.74, p > 0.4].
EXPERIMENT 4: AGE AND DRUG EFFECTS ON Bdnf SPLICE VARIANTS I,
IIc, III/IV, IV/VI
Bdnf mRNA exons change across age
Individual ANOVAs of exons I, IIc, III/IV, IV/VI were run to
determine significant changes across Age; only exon IIc and IV/VI
were significantly different [F(3,20) = 3.35 and 4.45, respectively,
p < 0.05; Figure 5]. Exons I and III/IV did not significantly
change across maturation (p > 0.6), nor did Bdnf total (p < 0.14).
Bdnf exon IIc and IV/VI mRNA, Drd3, and MPH exposure
No significant main effect of MPH exposure was evident at P60
(p > 0.7) for exon IIc. However, a strong correlation existed
between Drd3 and exon IIc [Pearson’s r = −0.73, p < 0.01;
FIGURE 4 | The effects of juvenile treatment with Veh, MPH, the D3R
antagonist nafadotride or MPH in combination with nafadotride on
Bdnf mRNA levels in the PFC following place conditioning. Means ±
SE are presented for n = 7–8 subjects/condition. ∗ indicates significant
difference at p < 0.05.
Figure 6 (left)]. Exon IV/VI was significantly reduced follow-
ing MPH exposure [F(1,10) = 42.43, P < 0.001], as shown in
Figure 6 (right), however, this relationship did not correlate with
changes in D3 receptors.
DISCUSSION
Our data show that juvenile exposure to MPH or manipulation of
the D3 dopamine receptor has enduring effects on the expression
of BDNF that are related to D3 receptor changes. D3R acti-
vation during development did not significantly change BDNF
protein levels, but increased Bdnf total mRNA while decreasing its
splice variants IIc and IV/VI in adulthood. A negative correlation
FIGURE 5 | Changes in mRNA expression of Bdnf and its exon-specific
splice variants I, IIc, III/IV, and IV/VI as a function of age. Data are
expressed following correction for GAPDH levels run simultaneously.
n = 5–6/age, with Means ± SE presented.
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FIGURE 6 | Relationship between D3R, MPH, and BDNF exon splice
variants. (left) Drd3 mRNA negatively correlates (Pearson’s r = −0.73)
with exon IIc expression. The filled squares represent the MPH subjects at
P60, whereas the open circles are Veh. (right) Juvenile treatment with
MPH significantly reduces exon IV/VI expression at 60 days of age relative
to the Veh. n = 6/group, with Means ± SE presented. ∗p < 0.05.
between Drd3 and exon IIc mRNA expression was observed. In
contrast, a reduction in Bdnf total mRNA and protein were evident
in CPP tested animals following D3 receptor activation during
development.
Bdnf gene regulation occurs in response to environmental
stimuli. As D3R antagonism attenuates cue-induced drug-seeking
behavior in adult animals (Gal and Gyertyan, 2005), the observed
decrease in Drd3 mRNA is consistent with a reduction in place
preferences for cocaine-associated cues in animals exposed to
MPH during the juvenile period (Andersen et al., 2002). More
importantly, changes in Bdnf and its association with Drd3 sug-
gest that the long-term plasticity observed in addiction (Sokoloff
et al., 2001) is reduced in MPH animals. Clinically, a subtype of
children that is treated with MPH shows reduced substance use
disorder (Mannuzza et al., 2008), suggesting that BDNF may play
a role.
A sensitive period exists for manipulations of PFC develop-
ment, with pre-pubertal exposure to psychostimulants offering
a window of opportunity for reduced substance abuse disorders
(SUD; Andersen, 2005). D3 receptors are localized on dopamine
terminals and non-terminal fields (Stanwood et al., 2000), which
continue to develop into adolescence (Andersen et al., 2008).
During adolescence, regulatory processes in the PFC change
markedly (Andersen et al., 1997; Dumont et al., 2004; Tseng and
O’Donnell, 2007) that lead to an increase in dopamine function.
One of these effects is the loss of a dopamine auto-regulatory-type
process mediated by D3 receptors (Booth et al., 1994; Andersen
et al., 1997). The current data show that D3R changes across age
account for 49% of the changes in Bdnf mRNA, suggesting that
D3R may differentially sculpt the pre- vs. post-adolescent PFC
by altering neurotrophic expression. Relative to controls, MPH-
exposed animals show a significant increase in Bdnf total mRNA,
but no changes in protein at baseline without challenge. However,
MPH animals had a reduction of Bdnf total mRNA and protein fol-
lowing cocaine conditioning. BDNF is released with dopamine in
the PFC in response to drug cues (Altar et al., 1998; McCarthy
et al., 2012). The adult literature shows that cocaine-induced
increases of BDNF suppress inhibitory GABAergic interneuron
activity in the mPFC [resulting in increased long-term poten-
tiation (LTP) (Lu et al., 2010)]. By extrapolation, a decline in
BDNF following juvenile MPH and drug challenge in adulthood
would reduce cortical output in response to drug cues relative
to controls. A recent study shows that juvenile MPH reduces the
number of spikes in PFC neurons in adulthood—consistent with
this hypothesis (Urban et al., 2012).
Modulation of BDNF occurs by histone acetylation or post-
transcriptional regulation (Mellios et al., 2008; Caputo et al.,
2011; Boulle et al., 2012; Leal et al., 2014), and our data provide
evidence for epigenetic modifications in BDNF splice variants
by MPH or D3R. In development, the splice variants II and
IV are typically decreased during the transition from juvenile
to adolescence. These exons were also reduced in adult animals
after juvenile MPH exposure. A negative correlation between
exon IIc and Drd3 mRNA suggests less neuronal plasticity as D3
receptors decrease either following typical aging or that facili-
tated by juvenile MPH treatment (Andersen et al., 2008). Exon
II has been localized to neurons and its expression is activity-
dependent in visual cortex (Pattabiraman et al., 2005), supporting
a potential role in modulating neuronal plasticity. Exon IV/VI
was also significantly lower in MPH subjects consistent with pre-
vious observations in juvenile MPH rats studied by Fumagalli
et al. (2010). It should be noted that the observed up-regulation
of Bdnf total mRNA in adult animals after juvenile treatment
with MPH did not correlate with BDNF protein levels. There
is emerging evidence that protein expression is regulated on the
post-transcriptional level by small non-coding RNAs, including
micro (mi) RNAs. Several miRNAs have been identified that tar-
get the Bdnf transcript (Mellios et al., 2008; Caputo et al., 2011),
indicating that other epigenetic mechanisms may be involved in
regulating BDNF expression.
The enduring effects in juveniles are predictably opposite
to the increase in Bdnf exon IV/VI expression in the PFC of
adult, cocaine self-administering rats that may underlie crav-
ing and relapse (Sadri-Vakili et al., 2010; Schmidt et al., 2013).
Exon IV/VI contains the binding sites for CREB and MeCP2
and plays a role in synaptic plasticity, cognitive processes and
learning andmemory—such as those required for encoding drug-
associated cues (McCarthy et al., 2012). While earlier studies
have demonstrated reduced cue responsiveness in rats exposed to
MPH during the juvenile period (Andersen et al., 2002; Carlezon
et al., 2003; Argento et al., 2012), others have shown that peri-
adolescent treatment with MPH reduces object recognition later
in life (Leblanc-Duchin and Taukulis, 2007). Interestingly, object
recognition increases following D3 receptor blockade in the adult
PFC (Watson et al., 2012). Together, these data suggest that MPH
may also permanently modulate object recognition later in life.
Object recognitionmeasures whether a novel object is recognized,
as new or not, which is impaired in ADHD.
Changes in BDNF are important during sensitive period when
the programming of drug-seeking behavior occurs (Andersen
et al., 2002; Andersen, 2005). Further understanding of the
molecular mechanisms regulating these changes can potentially
lead to novel ways of harnessing developmental relationships to
redirect an off-course trajectory. For example, Shaw et al. (2007)
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have shown that gray matter development of the PFC of ADHD
children and teens is delayed. Pharmacological targeting of BDNF
itself is difficult, but treatment with a D3R agonist pre-pubertally
may reduce behaviors that are associated with ADHD, including
risk for SUD, changes in object recognition, and activity levels.
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